secwatch.observer — SEC 8-K summary
======================================

Issuer:     FILANA THERAPEUTICS, INC. (FLNA)
CIK:        0001069530
Form:       8-K
Filed at:   2025-11-12T23:59:59+00:00
Accession:  0001171843-25-007222
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cassava Sciences Q3 net loss $10.8M; advances simufilam for TSC epilepsy
------------------------------------------------------------------------

- Net loss of $10.8M ($0.22/share) vs $27.9M loss ($0.58) in Q3 2024; cash $106.1M.
- Simufilam proof-of-concept study for TSC-related epilepsy expected to begin H1 2026.
- Appointed Joseph Hulihan as CMO (August 2025) and Dawn C. Bir to board (October 2025).
- Maintains $31.25M loss contingency for securities litigation settlement; timing unclear.
- Cash use guidance for second half 2025 revised downward; year-end cash est. $92-$96M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1069530/000117184325007222/0001171843-25-007222-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1069530/000117184325007222/f8k_111225.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-007222

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer